Cite
Caballero A, Filgueira LM, Betancourt J, et al. Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab. Clin Transl Immunology. 2020;9(11):e1218doi: 10.1002/cti2.1218.
Caballero, A., Filgueira, L. M., Betancourt, J., Sánchez, N., Hidalgo, C., Ramírez, A., Martinez, A., Despaigne, R. E., Escalona, A., Diaz, H., Meriño, E., Ortega, L. M., Castillo, U., Ramos, M., Saavedra, D., García, Y., Lorenzo, G., Cepeda, M., Arencibia, M., Cabrera, L., Domecq, M., Estévez, D., Valenzuela, C., Lorenzo, P., Sánchez, L., Mazorra, Z., León, K., & Crombet, T. (2020). Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab. Clinical & translational immunology, 9(11), e1218. https://doi.org/10.1002/cti2.1218
Caballero, Armando, et al. "Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab." Clinical & translational immunology vol. 9,11 (2020): e1218. doi: https://doi.org/10.1002/cti2.1218
Caballero A, Filgueira LM, Betancourt J, Sánchez N, Hidalgo C, Ramírez A, Martinez A, Despaigne RE, Escalona A, Diaz H, Meriño E, Ortega LM, Castillo U, Ramos M, Saavedra D, García Y, Lorenzo G, Cepeda M, Arencibia M, Cabrera L, Domecq M, Estévez D, Valenzuela C, Lorenzo P, Sánchez L, Mazorra Z, León K, Crombet T. Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab. Clin Transl Immunology. 2020 Nov 25;9(11):e1218. doi: 10.1002/cti2.1218. eCollection 2020. PMID: 33304584; PMCID: PMC7688906.
Copy
Download .nbib